Overview

A Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade Meningioma

Status:
NOT_YET_RECRUITING
Trial end date:
2028-01-13
Target enrollment:
Participant gender:
Summary
This is a randomized, controlled, open-label, multicenter, Phase II clinical study designed to evaluate the efficacy and safety of SYHA1813 compared to investigators' choice in participants with recurrent or progressive high-grade meningioma.
Phase:
PHASE2
Details
Lead Sponsor:
Shanghai Runshi Pharmaceutical Technology Co., Ltd